Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2012 April;53(2) > The Journal of Cardiovascular Surgery 2012 April;53(2):205-13

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

  ADVANCES IN BELOW-THE-KNEE MANAGEMENT


The Journal of Cardiovascular Surgery 2012 April;53(2):205-13

lingua: Inglese

Advances in below-the-knee drug-eluting balloons

Ferraresi R. 1, Centola M. 2, Biondi-Zoccai G. 3

1 Cardiovascular Interventional Unit, Istituto Clinico Città Studi, Milan, Italy;
2 Catheterization Laboratory, Cardiology department, Ospedale San Paolo, Milan, Italy;
3 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy


PDF  


The management of critical limb ischemia due to below-the-knee disease remains challenging due to the frequent patient comorbidities, diffuse vascular involvement, and high rates of restenosis and disease progression. The BASIL study has established the substantial equivalence between bypass surgery and percutaneous transluminal angioplasty in this setting, at least at mid-term follow-up, but percutaneous techniques and devices have seen major developments since the publication of this pivotal trial in 2005. A major breakthrough has indeed been the introduction of drug-eluting balloons, which have several theoretical advantages in comparison to standard balloons and metallic stents for infra-popliteal lesions. Two clinical trials have already been reported with favorable results for the In.Pact Amphirion paclitaxel-eluting balloon, when employed for below-the-knee lesions. We hereby discuss the rationale for the use of drug-eluting balloons in this complex setting and the main findings of the study by Schmidt et al. and the DEBATE-BTK trial.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

robertoferraresi@fastwebnet.it